High-Throughput Screening for RecA Inhibitors Using a Transcreener Adenosine 5′- O -Diphosphate Assay by Peterson, Eliza J.R. et al.
High-Throughput Screening for RecA
Inhibitors Using a Transcreener Adenosine
50-O-Diphosphate Assay
Eliza J.R. Peterson,1 William P. Janzen,2,3 Dmitri Kireev,2,3
and Scott F. Singleton1,2
1Department of Biochemistry and Biophysics,
School of Medicine; 2Division of Chemical Biology and
Medicinal Chemistry and 3Center for Integrative Chemical Biology
and Drug Discovery, UNC Eshelman School of Pharmacy;
The University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina.
ABSTRACT
The activities of the bacterial RecA protein are involved in the de novo
development and transmission of antibiotic resistance genes, thus al-
lowing bacteria to overcome the metabolic stress induced by antibac-
terial agents. RecA is ubiquitous and highly conserved among bacteria,
but has only distant homologs in human cells. Together, this evidence
points to RecA as a novel and attractive antibacterial drug target. All
known RecA functions require the formation of a complex formed by
multiple adenosine 5 0-O-triphosphate (ATP)-bound RecA monomers on
single-stranded DNA. In this complex, RecA hydrolyzes ATP. Although
several methods for assessing RecA’s ATPase activity have been re-
ported, these assay conditions included relatively high concentrations of
enzyme and ATP and thereby restricted the RecA conformational state.
Herein, we describe the validation of commercial reagents (Tran-
screener adenosine 5 0-O-diphosphate [ADP]2 fluorescence polariza-
tion assay) for the high-throughput measurement of RecA’s ATPase
activity with lower concentrations of ATP and RecA. Under opti-
mized conditions, ADP detection by the Transcreener reagent pro-
vided robust and reproducible activity data (Z 0 = 0.92). Using the
Transcreener assay, we screened 113,477 small molecules against pu-
rified RecA protein. In total, 177 small molecules were identified as
confirmed hits, of which 79 were characterized by IC50 values £10 lM
and 35 were active in bioassays with live bacteria. This set of com-
pounds comprises previously unidentified scaffolds for RecA inhibi-
tion and represents tractable hit structures for efforts aimed at




ew antibacterial strategies will be required to overcome the
looming public health threat posed by the combination of
an increasing prevalence of antibiotic-resistant bacterial
pathogens with a dwindling pipeline of new antibiotics.1,2
Significant scientific and environmental challenges remain in the
discovery and development of novel mechanism antibiotics.3 One
alternative to conventional antibiotic discovery would be the de-
velopment of adjuvants to enhance the outcomes of antibacterial
therapy. Recent studies demonstrate that bacterial strains with inactive
RecA enzyme are more susceptible than wild-type strains to killing by
antibacterial agents.4–7 Moreover, loss of RecA function also attenu-
ates the rates of induced mutagenesis and intrachromosomal recom-
bination upon antibiotic exposure, thereby slowing the development
of antibiotic resistance.6–8 RecA inactivation also diminishes the ef-
ficiency of horizontal gene transfer, hindering the acquisition and
dissemination of antibiotic resistance genes.9–11 Given this evidence,
we hypothesized that small-molecule RecA inhibitors could sensitize
bacteria to conventional antibiotics and attenuate the frequency with
which resistance genes develop and are transmitted.12 The discovery of
potent and selective RecA inhibitors that modulate the target in living
bacteria would be an important step in establishing RecA as a drug-
gable target in the management of bacterial infectious diseases.
RecA’s importance in the bacterial survival of and response to
antibacterial exposure arise from its cardinal roles in mediating the
SOS response and facilitating DNA strand exchange. All RecA activi-
ties require the formation of a helical homopolymeric filament com-
prising multiple adenosine 50-O-triphosphate (ATP)-bound RecA
monomers coating single-stranded DNA (ssDNA).13 Once formed, this
RecA-DNA filament (RDF) hydrolyzes ATP. Thus, monitoring ATPase
activity can be used as a diagnostic for small molecule inhibition of
RecA by in vitro screening.14–17 These previously reported assay
technologies had sensitivity limitations, requiring high concentrations
of enzyme ([RecA] ‡ 0.5mM) and substrate ([ATP] ‡ 0.75 mM). Under
such forcing conditions, RecA exists almost exclusively in an active,
DNA-bound conformational state, and inhibitors selective for this
conformation (Fig. 1A) were primarily identified.
ABBREVIATIONS: ADP, adenosine 50-O-diphosphate; aq, aqueous; ATP, adenosine 50-O-triphosphate; CICBDD, Center for Integrative Chemical Biology and Drug Discovery; D
buffer, detection buffer; FP, fluorescence polarization; HEPES, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; HTS, high-throughput screening; LOPAC, library of phar-
maceutically active compounds; poly(dT), polydeoxythymidylic acid; R buffer, reaction buffer; RDF, RecA-DNA filament; SD, standard deviation; ssDNA, single-stranded DNA.
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The development of a more sensitive screening assay with the
ability to detect low ATP turnover under reduced RecA and ATP
concentrations was desired. Under such nonforcing conditions, RecA
could sample both its inactive and active conformational states, fa-
cilitating the identification of additional small molecule inhibitors
without bias with respect to RecA conformational preference (Fig.
1B). Moreover, a reduced enzyme concentration would lower the
stoichiometric limit on measured IC50 values, and reduced ATP levels
would allow the identification of ATP competitive inhibitors.
Assay optimization under these desired conditions represented a
challenge because the equilibrium constant for RecA self-association
during filament assembly and activation is modest and its turnover
number for ATP hydrolysis is low (kcat £ 0.5 s - 1). The robust assess-
ment of RecA’s ATPase activity under such conditions required a
sensitive detection methodology.
The Transcreener adenosine 50-O-diphosphate (ADP)2 fluores-
cence polarization (FP) assay from BellBrook Laboratories (Madison,
WI) is a screening assay kit that allows ADP detection using an ADP-
antibody/tracer system with FP readout. Briefly, the Transcreener
ADP2 FP assay utilizes an antibody that selectively binds ADP to
quantify the ADP produced from an ATPase reaction. ADP conjugated
to AlexaFluor-633 dye is used as a tracer, and the amount of tracer that
is displaced from the antibody is proportional to the amount of ADP
generated in the reaction. This highly sensitive, homogeneous assay
technology has been used to study protein kinases,18 lipid kinases,19
and heat shock proteins.20 Moreover, the assays have proven to be
suitable for high-throughput screening (HTS).21 In the present study,
we report the adaptation of the Transcreener ADP2 FP assay to detect
the ATP hydrolysis activity of purified Escherichia coli RecA protein.
We demonstrate the ability of the assay technology to be optimized for
lower enzyme and ATP concentrations and its use in HTS of a diverse
collection of drug-like small molecules, leading to the identification of
novel RecA inhibitor scaffolds.
MATERIALS AND METHODS
Materials
The Transcreener ADP2 FP assay kit (cat. no. 3010-10K) was
purchased from BellBrook Labs. Polydeoxythymidylic acid (Poly[dT])
ssDNA was purchased from The Midland Certified Reagent Company
(Midland, TX). RecA was purified and stored as previously de-
scribed.22 Unless otherwise stated, all other reagents used for buffers
and assays were purchased from Fisher Scientific International
(Ipswich, MA).
LOPAC Compound Collection
The Library of Pharmacologically Active Compounds (LOPAC) was
purchased from Sigma-Aldrich as 10-mM stocks in dimethyl sulf-
oxide (DMSO). The library was previously prepared as 1-mL samples
in 384-well V-bottom polypropylene microplates (Greiner, Monroe,
NC), sealed by an ALPS 3000 microplate heat sealer (Thermo Fisher
Scientific, Hudson, NH) and stored at -20C. On the day of use, the
compounds were thawed and diluted to 150 mM (10· final concen-
tration) in reaction buffer (R buffer: 25 mM Tris-HOAc, 10 mM Mg
(OAc)2, 1 mM DTT, 5% glycerol, and 0.01% TritonX-100) over two
steps using a Thermo Scientific MultidropCombi Reagent Dispenser
(Waltham, MA) and Multimek NSX-1536 assay workstation system
fitted with a 384-well head (Nanoscreen, Charleston, SC). Finally,
1 mL of this stock was spotted into the wells of a 384-well black
PerkinElmer Proxiplate (Waltham, MA) for assay use, as described
below.
100k Diversity Screening Compound Collection
The 100k Diversity Collection of screening compounds was de-
veloped by structural chemists from St. Jude and the Center for In-
tegrative Chemical Biology and Drug Discovery (CICBDD).
Compounds were selected based on structural diversity at the Murcko
scaffold level.23 Essentially, a compound’s Murcko scaffold includes
contiguous ring systems plus chains that link two or more rings. For
Murcko scaffolds with more than 20 compounds, 20 compounds were
Fig. 1. Cartoons depicting the inactive RecA monomers and active RecA-
DNA filament (RDF). (A) Assay conditions, including high concentrations
of RecA, DNA, and ATP, shift the filament assembly and activation
equilibrium such that RecA exists almost exclusively in an active, DNA-
bound conformational state. Inhibitors identified under such forcing
conditions will be strongly biased toward binders of this conformational
state. (B) The desired assay conditions include 10-fold lower concen-
trations of RecA and ATP, and RecA samples both its inactive and active
conformational states during the assay. Such nonforcing condi-
tions would facilitate the identification of additional inhibitors without
bias with respect to RecA conformational preference as well as ATP-
competitive inhibitors. ATP; adenosine 50-O-triphosphate.
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randomly selected for that scaffold to maximize the diversity of
scaffolds in the Diversity Collection. Compounds were also filtered to
eliminate reactive function groups (REOS score > -2)24 and include
compounds that obey the ‘‘rule of five’’25 with slight deviations to
permit slightly larger and more lipophilic compounds. Based on the
above selection process, a set of 100k compounds was chosen and
purchased from Enamine Ltd (Kiev, Ukraine) in powder stock. At
random, around 5% of the collection was examined by LC/MS for
identity and purity confirmation. The compound collection plates
were prepared by resuspending the powder stock to 1 mM in DMSO in
barcoded glass vials with sonication using a Covaris S2 (Covaris,
Woburn, MA). Compounds were plated at 1 mM in 100% DMSO in
384-well V-bottom polypropylene microplates using a Tecan Genesis
200 (Münnedorf, Switzerland). A Multimek spotted 1 mL of the 1 mM
compounds into 384-well V-bottom polypropylene microplates and
plates were heat-sealed and stored at - 20C. During screening, these
previously prepared plates were thawed and diluted to 150 mM by a
single addition of R buffer, and 1mL of this stock was spotted into the
wells of a 384-well Proxiplate.
Kinase Focus Set
The Kinase Focus Set was designed by the CICBDD based upon a
combination of kinase pharmacophore-based searching and selection
from vendor kinase directed sets. The 4,727 compounds chosen for the
Kinase Focus Set were distinct from any in the Diversity Collection and
all were ‘‘rule of five’’ compliant.25 The Kinase Focus Set was acquired
from several vendors in powder stock. Compound and assay plates
were prepared as same as the 100k Diversity Collection.
Transcreener Assay
The assay was performed using a Multidrop dispenser to add 1mL
of 10% DMSO in the left two columns (columns 1 and 2) for positive
control reactions. In the right two columns (columns 23 and 24), 1mL
of 500 mM ethylenediaminetetraacetic acid (EDTA) was spotted for
negative control reactions. Assay reactions were carried out directly
in the Proxiplate wells containing 1-mL compounds or controls. The
reaction volume in each well was 10 mL, and the final concentration
of the compound and DMSO was 15 mM and 0.1%, respectively. A 2·
solution of RecA was prepared in R buffer. To all wells of the assay
plates, 4.5 mL of the 2· RecA in R buffer was added using a Multidrop
dispenser. RecA was allowed to preincubate with compounds and
controls for 20 min in a 37C air incubator. After preincubation, a 2·
cocktail of ATP and poly(dT) ssDNA in R buffer was added in a
volume of 4.5mL to each well. Immediately upon addition of the ATP/
poly(dT) mixture, assay plates were again transferred to the 37C air
incubator and the reaction was allowed to proceed for 30 min. After
30 min, the plates were removed and quenched by adding 10 mL of
2· Transcreener detection buffer (D buffer: 50 mM 4-(2-hydroxy-
ethyl)piperazine-1-ethanesulfonic acid [HEPES], pH 7.5, 400 mM
NaCl, 0.02% Brij-35, and 20 mM EDTA) with 4 nM Transcreener
AlexaFluor 633 ADP tracer, and 75 mg/mL ADP2 antibody. To ensure
uniformity of results, no more than 20 plates were processed at a time
during screening and plates were incubated at ambient temperature
for 30 min before reading on an EnVision Multilabel Reader (Perkin-
Elmer) using far-red FP filter set.
Compounds for dose–response runs were resuspended to 10 mM
in DMSO in barcoded glass vials. The representative selection hits
and Kinase Focus Set hits were sonicated using the Covaris S2
and plated as 3-fold dilutions over 10 points using the Tecan in
384-well V-bottom polypropylene microplates. The remaining
hits were resuspended and placed in a sonicating water bath if
needed for solubility. The dose–response curves of the remaining hits
were prepared as 3-fold dilutions over 10 points using a multi-channel
pipette. Compound titration series of all hits for IC50 evaluation were
spotted at 1mL by a Multimek instrument into 384-well V-bottom
microplates and diluted 20-fold in R buffer using a Multidrop dis-
penser. The diluted titrations were then spotted at 1mL into 384-well
black Proxiplates in duplicate or triplicate, and reagents were added to
initiate the assay as described above. The final top concentration of
dose–response curves was 50mM compound (0.5% DMSO).
Data Analysis
The FP of the ADP tracer was measured using the far-red FP filter
set from PerkinElmer (optimized Cy5 FP Dual Emission label, 620/
40 nm excitation filter, 688/45 nm emission filter, and D658/fp688
dual mirror) with the G factor set at 0.64. The emission values were
calculated to a milli-polarization (mP) signal using the following FP
fit sequence:
mP = 1000 · (S - G · P)=(S + G · P)
where G is the G-factor (0.64), S is the emission filter parallel to the
excitation filter, and P is the emission filter perpendicular to the
excitation filter.
Screening data were processed using ScreenAble software
(Screenable Solutions, Chapel Hill, NC). The percent inhibition was
determined on a plate-to-plate basis by comparing the calculated mP
value per compound well with the plate-averaged control wells
(n = 32 for each control), using the following relationship:





where mP is the compound well mP signal, and linh and lmax are the
plate-averages of the minimum signal (maximum ATPase activity,
1% DMSO added) and maximum signal (inhibited, 50 mM EDTA
added) controls, respectively.
The Z 0 factor was calculated for each assay plate to assess the
quality and robustness of the HTS. The Z 0 factor was determined
using the following formula:




where rmax and rmin are standard deviations (SDs) in respective plate
maximum and minimum signal controls, and lmax and lmin are the
plate-averages of the respective controls, as defined above.
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Compound IC50 values were calculated by first converting the mP
signal to percent inhibition with respect to on-plate controls and then
fitting the percent inhibition values to curve equations using
ScreenAble or Prism (GraphPad Software, San Diego, CA). The IC50
values of the representative selection hits and Kinase Focus Set hits
were calculated using ScreenAble with a 3- or 4-parameter curve fit.
The remaining hits were analyzed in Prism using a one-site-specific
binding with Hill slope and Bmin.
Selection of Representative Active Compounds
The representative compounds were selected according to the
following procedure. First, all 235 actives from the 100k Diversity
Collection were grouped into compact clusters of similar compounds.
More specifically, the similarity between any two compounds within
a cluster was at least 65% according to the Tanimoto metrics with
ECFP4 fingerprints (Pipeline Pilot, ver 7.5; Accelrys Software, Inc.;
2009). The clustering procedure revealed 22 clusters (of 3–10 com-
pounds) and 92 singletons—that is, compounds that did not have any
structural analogs among the 235 hits. Despite being outliers among
the hits, most of 92 singletons had numerous structural analogs that
did not show any activity in the Transcreener assay. These com-
pounds were assigned a lower priority because of a high risk of them
being either false positives or intractable hits. Finally, the first pri-
ority representative subset of 78 compounds consisted of 3 com-
pounds per cluster that showed the highest response in the primary
high-throughput screening (i.e., 66 actives) and 12 true singletons
(i.e., hits that did not have any structural analogs neither among
other hits nor among the inactive compounds).
RESULTS
Assay Development and Validation
Previous reaction conditions used for measuring RecA’s ATPase
activity required relatively high concentrations of RecA and ATP. To
lower enzyme and substrate concentrations, we optimized the con-
ditions of the Transcreener ADP2 FP assay to our desired levels of
enzyme and ATP. We also assessed the robustness, reproducibility,
and HTS compatibility of the Transcreener assay to ensure its success
in screening collections of diverse drug-like small molecules for the
inhibition of RecA.
An ADP/ATP standard curve was produced (Fig. 2A), as described
in the TranscreenerADP2 FPassay technical manual.26 The experi-
ment simulates the production of ADP during the course of a RecA-
catalyzed ATP hydrolysis reaction and the expected decrease in FP
signal (mP) was observed. The ATP concentration required for half-
maximal steady-state velocity, or S0.5 for cooperative enzymes such
as RecA,27 depends on the reaction conditions, and published values
range from 2.5 to 200 mM.12,28 In the presence of poly(dT) as the
activating DNA, RecA’s ATPase activity was measured with initial
ATP concentrations from 25 to 100 mM. It was found that 75 mM was
the lowest concentration that resulted in linear (steady-state) kinetics
for nearly 40 min with an acceptable signal-to-background ratio.
Subsequently, under the optimized ATPase screening conditions
described below, the apparent S0.5 was measured to be 88 mM (data
not shown). Because a substrate concentration equal to or slightly
less than the KM (S0.5) value in HTS campaigns allows the identifi-
cation of all types of inhibitors, including those that are competitive
with substrate,29 we selected 75 mM as the ATP concentration and
optimized the other assay parameters.
In the presence of 75 mM ATP and a saturating concentration of
poly(dT) (5 mM-nts), RecA’s ATPase activity increased monotoni-
cally with initial RecA concentration (data not shown). A RecA
concentration of 30 nM was selected for further experiments be-
cause this was the lowest RecA concentration to produce approxi-
mately linear enzyme activity over a reasonable time range and
sufficient conversion to achieve an adequate signal window. Op-
timized conditions included 30 nM RecA, 75 mM ATP, and 5 mM-nt
spoly(dT). Employing these conditions, the ADP concentration
produced at 37C was measured over time by comparison with an
ADP standard curve (Fig. 2B). The Transcreener assay demonstrated
linear ADP production kinetics to 40 min, and we elected to use
30 min as the reaction time to remain comfortably within the as-
say’s linear dynamic range.
Fig. 2. Assay optimization with respect to (A) ATP/ADP signal, (B) time and enzyme dependence, and (C) DMSO tolerance determined in
384-well format. (A) ATP/ADP titration, with a constant adenosine concentration of 75 mM. (B) Reaction time course in the () presence or
(B) absence of 30 nM RecA. (C) FP (mP) signal after 30-min RecA ATPase reaction in the presence of various amounts of DMSO. The data
presented are mean – standard deviation (SD) of triplicate wells (n = 3). FP, Fluorescence polarization.
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It is common for small-molecule library samples to be dissolved in
DMSO in preparation for screening. Therefore, the effect of DMSO on
RecA activity was investigated at several different DMSO concen-
trations, up to 10% (vol/vol) (Fig. 2C). There was no significant re-
duction in RecA ATPase activity by DMSO up to the highest
concentration tested and the final DMSO concentration used for
screening was 0.5%–1% (vol/vol).
To assess the reproducibility of the Transcreener assay, a number
of test 384-well plates were evaluated for intercolumn, interplate,
and interday variability. Over a span of 3 days, eight replicate assay
plates were run under the optimized conditions described above and
used to compile the mean control signals (Fig. 3) for Z 0 factor cal-
culation.30 The maximum activity controls (128 per plate, even col-
umns of a 384-well plate) consisted of wells containing RecA, DNA,
ATP, and 1% DMSO in buffer. The background or inhibited controls
(128 per plate, odd columns of a 384-well plate) consisted of wells
containing RecA, DNA, ATP, and 50 mM EDTA in buffer. The FP
signal was read at 30 min and the overall quality of the Transcreener
assay was assessed using the Z 0 factor. Characteristic of a high-
quality assay, the average Z 0 factor was 0.85 and consistent
throughout the validation run.
Screen Design and Pilot Study
Using the protocol outlined in Table 1, the Transcreener assay was
employed to screen the LOPAC as a pilot study. The LOPAC comprises
1,280 biologically active compounds and was assessed in triplicate
for RecA inhibition at a final compound concentration of 15 mM. The
LOPAC pilot screen was characterized by an average Z 0 factor of 0.76,
and 19 compounds were identified with average relative inhibition
activities ‡ 75% inhibition as an average of three replicates (Fig. 4A).
This active threshold of 75% inhibition represented 6 SD above the
mean and provided a hit rate of 1.5%. As shown in Figure 4B, the pilot
screen also demonstrated strong correlation between replicates.
Analysis of the three replicates revealed five compounds as false
positives and an estimated false positive rate of 0.4%.
The LOPAC was screened previously against RecA using a different
ATPase assay16 under different conditions, and 9 of the 19 active
compounds were identified as RecA inhibitors by both assays. The
high correspondence of the active compounds confirmed the Tran-
screener assay as a reliable method for identifying RecA inhibitors
from large compound libraries. Importantly, however, the fact that
previously unidentified RecA inhibitors were identified using the
Transcreener assay substantiated our assay design and demonstrated
the ability to explore new chemical space for RecA inhibitors.
Fig. 3. Assay validation over multiple plates and multiple days.
Each data point represents the mean FP (mP) signal of 128 wells
from 3 different experiments on 3 different days (2 or 3 plates per
experiment); the error bars indicate the SD of each mean value.
The (B) represent the mean values for the background or inhibited
controls (50 mM EDTA final) and the () represent the mean values
for the maximum activity controls (1% DMSO final). EDTA, ethyle-
nediaminetetraacetic acid.
Table 1. High-Throughput Screening Assay Protocol
Step Parameter Value Description
1 Library compound 1 mL 10 · in R buffer containing
10% (v/v) DMSO; 15 mM final
2 Controls 1 mL 10 · ; 1% DMSO and 50 mM
EDTA final
3 RecA 4.5mL 2 · in R buffer; 30 nM final




4.5mL 2 · in R buffer; 75 mM ATP
and 5mM poly(dT) final
6 Incubation 30 min 37C
7 Antibody and tracer 10 mL 2 · in D buffer; 37.5mg/mL
antibody & 2 nM tracer final
8 Assay readout After
30 min
EnVision Multilabel Reader
using far-red FP filter set
Step Notes
1. Multimek transfer to 384-well plates (tip wash 5 · with 20 mL of dH2O).
2. 10% aqueous DMSO added to columns 1 and 2; 500 mM EDTA added to
columns 23 and 24.
3. 8-tip Multidrop dispense reagent to all wells.
4. Plates uncovered in nonshaking incubator.
5. 8-tip Multidrop dispense reagent to all wells.
6. Plates uncovered in nonshaking incubator.
7. 8-tip Multidrop dispense reagent to all wells.
8. Plates kept uncovered at 25C in dark for 30 min until read on multilabel
reader using the PerkinElmer Cy5 FP dual emission label (620/40 nm
excitation filter, 688/45 nm emission filter, and D658/fp688 dual mirror).
ATP, adenosine 50-O-triphosphate; D buffer, detection buffer; DMSO,
dimethyl sulfoxide; EDTA, ethylenediaminetetraacetic acid; FP, fluorescence
polarization; R buffer, reaction buffer.
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Screening
Although the pilot screen provided a number of novel inhibitors of
RecA, our main objective in screening the LOPAC was to validate the
Transcreener assay as robust and reproducible for the evaluation of
additional libraries containing compounds with greater potential for
development as small-molecule therapeutics. Towards this end, we
screened 113,477 compounds from collections at CICBDD at the
University of North Carolina at Chapel Hill. Compounds from the
100k Diversity Collection and the Kinase Focus Set were screened
against RecA in singleton at 15 mM from 1 mM DMSO stocks using
the Transcreener assay. The Diversity Collection screening results
demonstrated a normal distribution centered on a mean of 0% in-
hibition with an SD of 5% (Fig. 5A). Similarly, the Kinase Focus Set
screen gave a mean of - 0.9% and an SD of 7% (data not shown).
Overall, the average Z 0 factor was 0.92 for the 359 analyzed plates
(Fig. 5B). A single plate fell below the 0.6 minimum Z 0 factor ac-
cepted value and was repeated before inclusion in data analysis.
As summarized in Table 2, the 100k Diversity Collection primary
HTS resulted in a total of 235 compounds with >30% inhibition. The
activity threshold was set at 30% inhibition and defined as 6·SD
above the mean. The 30% inhibition cut-off was stringent by
screening standards and yielded a sufficient number of hits for fol-
low-up (0.22% hit rate). From the 235 initial hit compounds, 78
compounds were selected based on their structural representativity23
for IC50 determination as described in Materials and Methods. The
remaining 157 (of 235) hits were labeled as the ‘‘remaining hits’’ and
given a second priority in our activity analysis.
We performed a concentration–response study of all the available
HTS initial hits using the Transcreener assay. From the representative
selection, 77 compounds were available in powder stock for evalua-
tion. The concentration–response measurements were performed in
triplicate and 66 compounds were characterized by IC50 £ 35mM (Table
2). The validation rate of the representative selection set was 86%, and
nearly half of the inhibitors were characterized by IC50 £ 10mM.
Of the remaining hits, 154 compounds were obtained in powder
form and were similarly evaluated by IC50 measurement in triplicate.
The concentration–response curves allowed 84 compounds to be
characterized by IC50 £ 35 mM (Table 2). The validation rate of the
Fig. 4. Results from the LOPAC pilot screen.
(A) Scatter plot of the mean relative inhibition
effected by 4,727 compounds from the LOPAC
collection against RecA using the Transcreener
assay. The data presented are mean – SD of
triplicate wells (n = 3). (B) Correlation plot
of the mean relative inhibition from two runs
of RecA LOPAC screen with solid line indicat-
ing perfect 1:1 correlation. LOPAC, library of
pharmaceutically active compounds.
Fig. 5. HTS results. (A) Frequency distribution of the 100K Diversity
Collection relative inhibition results depicted as a histogram,
where the number of compounds in each bin ( – 1% width) is
plotted on a linear scale. Inset displays the frequency distribution
of bins ( – 1% width) with greater than 20% inhibition. (B) Z 0 factor
analysis of the 359 plates assayed during 100K Diversity Collection
and Kinase Focus Set HTS. 32 wells of inhibited controls (50 mM
EDTA final) and 32 wells of maximum activity controls (1% DMSO
final) were used to calculate the Z 0 factor. Dashed line indicates Z 0
factor value established as minimum threshold for accepted plates
to be included in data analysis.
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remaining hits (55%) was lower than that of the representative se-
lection set, but still confirmed over half as validated biochemical
RecA inhibitors. The high validation rate of the representative se-
lection set was a result of our structural grouping analysis of the HTS
results to prioritize the more potent inhibitors.
The Kinase Focus Set was collected by the CICBDD and comprised
4,727 kinase-directed drug-like small molecules not found in the 100k
Diversity Collection. Given that both kinases and RecA are ATP-de-
pendent enzymes, a compound library with small molecules directed at
kinases was screened with hopes that it might present compounds
active against RecA ATPase activity. The screen yielded 14 compounds
with ‡ 43% inhibition (6 · SD above the mean). The 0.3% hit rate was
similar to the Diversity Collection screen. The IC50 determination of the
14 initial hits was performed in duplicate from powder stocks and
validated 12 compounds as having IC50 £ 35mM (Table 2).
Raw data for three replicates of a validated hit compound are
depicted in Fig. 6. There is a clear dose-dependent inhibition of en-
zyme activity over 6 concentrations tested. A reproducible IC50 of
5 – 1 mM confirms the robustness and reproducibility of the assay.
Follow-up Evaluation of Select Inhibitors
Further evaluation revealed that many of the inhibitors were ac-
tive in biological assays with live E. coli and were characterized
by biochemical mechanisms of inhibition that differed from those
of known RecA inhibitors. Of the 165 validated hits from the 100k
Diversity Collection, 35 were active in one or more bacteriologi-
cal assays for SOS activation or fluoroquinolone antibacterial
potentiation. We then selected 15 inhibitors that were active in bio-
assays with live bacteria, were characterized by IC50 values < 10mM in
the Transcreener assay, or both. For the 15 selected inhibitors, ATPase
rates were measured as a function of substrate ATP concentration
at different inhibitor concentrations. Analysis of resulting velocity–
ATP concentration curves unexpectedly revealed that none of the
compounds exhibited competition with ATP; however, 13 compounds
were noncompetitive inhibitors and 2 were mixed-type inhibitors
with a> 1.31 Similar characterization of RecA inhibitors identified by
previous assays14–17 revealed only ATP-uncompetitive and DNA-
competitive inhibitors, results that were consistent with restricted
specificity for the active conformational state of the RecA filament.
Although we expected some of the tested compounds from the Tran-
screener assay to competitively bind the ATP site, the discovery of
inhibitors that target both free RecA enzyme and the substrate-bound
conformation of RecA confirmed the successful identification of RecA
Table 2. Summary of Successful High-Throughput
Screening for RecA Inhibitors
Library: 100k Diversity Compound Collection
Number of compounds tested 108,750
Overall primary screen hit rate (%) 0.22
Overall number of hit compoundsa 235
Number of hit compounds in representative selectionb 78
Validation rate from representative selection (%) 86
Number of validatedc hits from representative selection 66
Number of remaining hit compoundsd 157
Validation rate of remaining hits (%) 64
Number of validated hits from remaining hits 99
Overall validation rate (%) 71
Overall number of validated compounds 165
Overall number of compounds with IC50 £ 10mM 74
Library: Kinase Focus Set
Number of compounds tested 4,727
Hit rate (%) 0.30
Number of initial hitse 14
Validation rate (%) 86
Number of validatedf hits 12
Number of compounds with IC50 £ 10 mM 5
aAll compounds with ‡ 30% inhibition (6 · SD above the mean).
bCompounds with ‡ 30% inhibition and selected based on their scaffold
group. See text for selection details.
cCompounds with IC50 £ 35 mM with visual inspection of curve shape and
max % inhibition ‡ 60%.
dRemaining compounds with ‡ 30% inhibition.
eCompounds with ‡ 43% inhibition (6 · SD above the mean).
fCompounds with IC50 £ 35mM.
Fig. 6. Reproducible concentration–response measurements for
validated inhibitor UNC10036220 from the 100k Diversity Collec-
tion screen. The curve representing the mean IC50 value of 5 – 1mM
was consistent with data from three independent runs (circle,
square and triangle symbols, respectively).
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inhibitors with varied specificity for RecA conformation. A full ac-
counting of these results will be reported elsewhere.
DISCUSSION
RecA facilitates important biological processes that allow bacteria
to survive and respond to antibacterial exposure. Because RecA is
ubiquitous32 and highly conserved33 among bacteria, but has only
distant human homologs,13,34–38 potent and selective RecA inhibitors
may serve as novel chemotherapeutic adjuvants to enhance con-
ventional antibiotics. Although we have previously developed bio-
chemical assay technologies that allowed target-based screening to
identify RecA inhibitors, the prior assay conditions restricted both the
available conformational state of RecA and the inhibitor mechanistic
types that could be explored. A major conclusion of this work is that
the Transcreener ADP2 FP assay method could be adapted for a robust
and reproducible HTS (Z 0 = 0.92) of 113,477 small molecules for in-
hibition of RecA ATPase activity. The sensitivity of the Transcreener-
ADP2 FP technology allowed the enzyme and substrate concentrations
to be reduced by more than an order of magnitude. From the com-
pounds identified as active in the primary HTS assay, 246 compounds
were evaluated in concentration–response format and 79 inhibitors
characterized by IC50 £ 10mM were identified. Importantly, the eval-
uation of a subset of the inhibitors revealed 35 that were active in one
or more assays with live E. coli and that a number of new mechanistic
types and selectivities for RecA conformational states were identified.
These novel RecA inhibitors represent a variety of chemotypes and 33
unique scaffold groups (group size > 1) that will serve as synthetically
tractable hit series for medicinal chemistry efforts aimed at optimizing
biochemical and bacteriological inhibition of RecA activities.
In part, the continued search for new RecA inhibitors is motivated
by the increasingly urgent public health threat posed by antibiotic-
resistant pathogens. It is now clear that the use and misuse of anti-
biotics has played major roles in the selection and spread of resistant
pathogens. The exposure of bacteria to antibacterial compounds re-
sults in the selection of resistant variants that ultimately dominate
the population. Importantly, however, recent studies suggest that
bacteria are not merely passively subjected to natural selection but
can actively promote genetic diversification. The origins of genetic
variation include local changes in the DNA sequence (mutation),
intrachromosomal shuffling of DNA sequences (recombination), and
the acquisition of DNA sequences from other organisms (horizontal
gene transfer). Induced mutagenesis in response to antibiotic expo-
sure dramatically accelerates bacterial mutation.7,39–41 Likewise,
recombination plays a major role in bacterial evolution,7,42–44 and
may be a more frequent source of nucleotide changes in E. coli than
de novo mutation.45 Finally, horizontal gene transfer is an important
source of genetic diversity in bacteria.10,46–48
The genetic diversification processes described above are regu-
lated by the bacterium and depend on the function of select proteins
and enzymes, including RecA. Indeed, RecA has multiple functions
that contribute to induced mutation, intragenomic recombination,
and horizontal gene transfer, including induction of the SOS re-
sponse by stimulating autocleavage of the LexA repressor, activation
of error-prone DNA polymerase V by stimulating autocleavage of
UmuD, and facilitation of homologous genetic recombination. The
biochemical dependency of these phenomena on RecA activities
suggests that potent, selective RecA inhibitors could be developed to
attenuate the development, acquisition, and dissemination of resis-
tance, affording an opportunity to inhibit evolutionary processes and
enhance antibacterial chemotherapy. Current experiments are un-
derway to evaluate the inhibitors of RecA’s DNA-dependent ATPase
activity in bacteriological assays.
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